Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Human-Derived Mesenchymal Stem Cell Conditioned Medium for Inflammatory Diseases
jRCT1051250159Recruiting
- Sponsor
- Shin Yokohama Kato Clinic
- Start
- Dec 2025
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 2
01
Overview
Open-label, single-arm trial of ACT-20-CM in Inflammatory Disorders, sponsored by Shin Yokohama Kato Clinic. Primary endpoint: Serum C-reactive protein levels. Started Dec 2025; status: recruiting.
02
Drugs
ACT-20-CM
03
Conditions
Inflammatory Disorders
Beyond the preview
Go deeper on jRCT1051250159.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1051250159.